Clay Siegall: Changing The Face Of Cancer


When Dr. Clay Siegall founded Seattle Genetics, he had one focus in mind: to help those suffering with cancer in finding treatments that improve outcomes and lessen the effects of harsh cancer treatments. Since 1998 Seattle Genetics has been on the leading edge of developing new cancer medications starting with the research and development of antibody drug conjugates, specifically the drug ADCETRIS, which is the first drug approved by the FDA for multiple applications.

Dr. Siegall’s company started as a small company with a tiny crew of people has now grown into a drug powerhouse with a larger staff. Clay is the CEO of the company and does assist with research, but his role has changed to largely raising funds for research and development. Getting a medication tested and approved through the FDA is a long and expensive process so getting the funds raised and sustaining a even level of funding is important to Seattle Genetics. ADCETRIS dose help fund more research and the drug will be exclusively owned by Seattle Genetics for a few more years. There are also some licensing items and partnerships that earn revenue for Seattle Genetics.

Dr. Clay Siegall’s past history is very well suited to this career. Clay knew he wanted to devoted his life to bettering cancer research after a loved one had went through a though battle with cancer. Dr. Siegall graduated with a bachelor’s degree in Zoology from the University of Maryland and later a PhD in Genetics from George Washington University. Clay has worked for most of his career in research for the better treatment of cancer with National Cancer Institute, National Institutes of Health and with a research division of Bristol Meyers Squib.

After gaining twenty plus years in the field of cancer research, Clay decided to start his own company because he wanted to see his research come to life and be involved in the process from start to finish. Dr. Clay Siegall also enjoyed that he would like to see his hard work and ideas financially pay off for himself and others instead of handing his research over to a company he worked for.